Direxion Daily Pharmaceutical & Medical Bull 3X Shares (ARCA: PILL)

에 대한 최신 뉴스 Direxion Daily Pharmaceutical & Medical Bull 3X Shares (ARCA:PILL)

Direxion Daily Pharmaceutical & Medical Bull 3X Shares

Healthcare

Direxion

The fund invests at least 80% of its net assets (plus borrowing for investment purposes) in financial instruments and securities of the index, ETFs that track the index and other financial instruments that provide daily leveraged exposure to the index or ETFs that track the index. The index is a modified equal-weighted index that is designed to measure performance of the stocks comprising the S&P Total Market Index that are classified in the GICS pharmaceuticals sub-industry. The fund is non-diversified.

Dreyfus Govt Cash Man Ins

Goldman Sachs Fin Gov 465 Institut

Axsome Therapeutics, Inc

Viatris Inc.

Eli Lilly & Co.

Pfizer, Inc.

Catalent, Inc.

Gs Financial Square Treasury Instruments Fund

Tarsus Pharmaceuticals Inc

Jazz Pharmaceuticals Plc

Rpi International Holdings Lp P/P

Bristol-Myers Squibb Co.

Intra-Cellular Therapies Inc

Corcept Therapeutics Inc

Perrigo Company, Plc

Johnson & Johnson

Elanco Animal Health Inc.

Zoetis  Inc .

Donald Trump Shutterstock

News

Health Care

Markets

FTXH

iShares Dow Jones US Pharmaceuticals Index Fund

KURE

PILL

Merrill Lynch Pharmaceutical HOLDRs Trust

지난주 도널드 트럼프 대통령이 약가 인하 행정명령에 서명한 후, 전문가들은 제약사들이 가격 결정력이 떨어지는 가운데 마진 축소 가능성에 직면해 있는 가운데 처방약급여관리업체(PBM)가 가장 큰 타격을 받을 수 있다.

트럼프의 약가 인하 행정명령, PBM에 가장 큰 타격···CVS헬스, 시그나, 유나이티드헬스 주목

Eli Lilly and Co.

Equities

Government

ABBV

AMGN

GILD

REGN

도널드 트럼프 대통령은 수요일(9일) 상호관세를 90일 동안 일시 중단했지만, 나중에 집무실에서 기자들과의 대화에서 제약 회사들이 관세에 직면할 것이라고 확인했다. 

트럼프의 의약품 관세 확인...일라이릴리·애브비·리제네론·브리스톨 등 제약주 급락

PILLARSTONE CAPITAL REIT by Pillarstone Capital REIT

PILLARSTONE CPTL REIT PFD by Pillarstone Capital REIT

Pillar

Pillar Corp

Pillarstone Capital REIT

Pillarstone Capital REIT 9.50% PRF PERPETUAL USD 10 - Cls A9.50% PRF PERPETUAL USD 10 - Cls A

As we head into the second half of 2025, the British economy is showing signs of stabilization, but it remains a structurally sluggish environment. The UK managed to avoid a technical recession in 2024, and GDP is growing again.
Just barely.
Annualized growth is running in the 0.5% to 1% range, which is below trend and well behind both the U.S. and parts of Europe.
The Bank of England has been slower to pivot than the Fed, with policy rates still above 4%, and a bias toward caution given persistent services inflation.
Real wages have begun to rise after two years of erosion, but the improvement has not meaningfully lifted consumer sentiment. High housing costs, weak productivity, and a stubbornly large fiscal deficit continue to weigh on growth.
&nbsp;The labor market remains tight, although immigration and increased participation have helped moderate wage pressures.
The structure of the mortgage market is a key differentiator from the U.S. Most UK mortgages are either variable-rate or short-term fixed, so the impact of higher interest rates has been more immediate.
That has restrained consumer spending in a way we have not seen in the U.S., where long-dated fixed-rate mortgages offer households more protection.
Commercial real estate in London is holding up relatively well, supported by overseas capital and demand for legal and financial services office space.
&nbsp;Outside of the capital, the picture is less stable, especially in regional offices and retail. The housing market remains sluggish, with transaction volumes down and affordability stretched.
On the equity side, UK stocks are still cheap. The FTSE 100 and broader FTSE All-Share index trade at forward price-to-earnings ratios in the 9 to 11 times range.
&nbsp;Price-to-book ratios are often below 1.5. That compares to the S&amp;P 500 at over 21x forward earnings and a price-to-book closer to 4.5.
&nbsp;Dividend yields on UK shares average between 4% and 4.5%, more than double the current yield on the S&amp;P.
Part of this valuation gap is structural. The UK market is heavily skewed toward energy, materials, financials, and consumer staples. It lacks the high-growth tech concentration that dominates the U.S. index.
&nbsp;The result is that UK stocks often look like value traps to growth-focused global investors.
There is a case to be made for British equities from an income and contrarian value perspective. Private equity firms and sovereign wealth funds continue to quietly buy up UK assets, particularly in the mid-cap space where valuations are even more depressed.
&nbsp;There is a clear disconnect between public market pricing and private market interest.
The outlook is not without risk. The UK is headed into a general election, with polls suggesting a change in government.
&nbsp;Markets may welcome more fiscal discipline, but any shifts in tax or regulatory policy could inject uncertainty.
Absent a stronger domestic growth story or a revival in innovation-led sectors, the valuation discount to U.S. stocks is likely to persist according to the experts.
Fortunately I thrive on ignoring the market and economics experts.
&nbsp;British equities offer a very different proposition from U.S. large caps.
&nbsp;Less growth, more income. Less enthusiasm, more defensiveness.
Sounds Perfect.
As the grandchild of Irish Immigrants, I am probably not supposed to recommend anything British but safe and cheap is too good to pass up no matter its nationality, accent or tendency to overcook perfectly good food.
Here are four UK-rooted names I am keeping a close eye on, each with its own catalyst and story.
CNH Industrial (Ticker: CNH) remains a global force in the agricultural and construction equipment space. Best known for brands like Case IH and New Holland, CNH has emerged from its restructuring with a leaner focus and a sharper edge. Following the spin-off of its truck and powertrain business into Iveco, CNH is doubling down on precision agriculture and automation. Yes, farm equipment demand has softened a bit, but CNH trades at just under 8x forward earnings and around 90% of book value. These are levels that already reflect a lot of caution.
In the meantime, the dividend yield sits near 3.1%, and the company continues to reinvest for long-term growth in smart farming and electrified machinery. For patient investors, the reward-to-risk balance looks favorable.
Nomad Foods (Ticker: NOMD) offers another quietly consistent story. As the parent of Birds Eye, Iglo, and Findus, Nomad is a dominant player in the European frozen food space. Frozen food may not sound exciting, but the business is sticky, recession-resistant, and generates a ton of cash.
Nomad's leadership team, which includes veteran operators and dealmakers, has done a solid job of balancing margin expansion with bolt-on M&amp;A. The stock trades at less than 10x forward earnings and carries a free cash flow yield of around 10%. There's no dividend here, but management has been actively repurchasing shares.
&nbsp;For investors looking for dependable cash flow at a discount, this one fits the bill.
Pearson (Ticker: PSO) is a classic example of a UK firm reinventing itself. Once known for textbooks and standardized tests, Pearson has transformed into a digital education company. The company now focuses on online learning, virtual testing, and credentialing services, with a strong push into direct-to-consumer platforms.
While the pivot has not been without bumps, the underlying fundamentals have improved. Pearson trades around 12x earnings and yields about 2.3%, with a modest payout ratio that leaves room for growth.
As global demand for online education and upskilling continues to grow, Pearson looks increasingly well-positioned to capitalize on this long-term shift.
Cushman &amp; Wakefield (Ticker: CWK), while operationally headquartered in Chicago, is technically domiciled in London and still reflects UK corporate governance roots. It is one of the largest commercial real estate services firms in the world, competing with CBRE and JLL. CWK has been through the wringer with the broader office market, but its facilities and outsourcing segments remain solid.
The real story here is valuation.
Shares are trading at just 8x forward earnings, a level that discounts a lot of bad news. The company has been paying down debt and preserving cash. In a world where deep value is hard to come by, CWK stands out as a name with real asset exposure, global scale, and the potential for mean reversion once commercial real estate stabilizes.
All four companies reflect the type of disciplined, cash-generating businesses that do not always get the headlines but often reward patient investors.
US Investors are focusing on deciding which news to ignore while chasing high multiple stocks.
Across the pond we can find some quality companies at bargain prices worthy of attention from&nbsp; patient aggressive investors
Whether it is agriculture, frozen foods, education, or real estate, these companies offer a chance to diversify geographically without leaving the comfort of U.S. markets.

Opinion

Under the Radar: Income and Discipline Over Hype and Hope

Roth Capital analyst Joe Reagor reiterates U.S. Gold (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAU#NASDAQ">USAU</a>) with a Buy and raises the price target from $16 to $18.

Price Target

Reiteration

Analyst Ratings

USAU

Roth Capital Reiterates Buy on U.S. Gold, Raises Price Target to $18

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Industrials sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>GE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$250.00</td>
<td>$45.3K</td>
<td>1.4K</td>
<td>6.3K</td>
</tr>
<tr>
<td>EMR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$120.00</td>
<td>$32.7K</td>
<td>382</td>
<td>1.6K</td>
</tr>
<tr>
<td>BA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/25/25</td>
<td>$210.00</td>
<td>$118.8K</td>
<td>847</td>
<td>1.4K</td>
</tr>
<tr>
<td>DOV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$190.00</td>
<td>$71.9K</td>
<td>4.1K</td>
<td>1.0K</td>
</tr>
<tr>
<td>FTAI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$130.00</td>
<td>$42.5K</td>
<td>2.4K</td>
<td>914</td>
</tr>
<tr>
<td>PNR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$110.00</td>
<td>$92.5K</td>
<td>412</td>
<td>500</td>
</tr>
<tr>
<td>LYFT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$16.00</td>
<td>$25.1K</td>
<td>12.9K</td>
<td>303</td>
</tr>
<tr>
<td>FDX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$280.00</td>
<td>$34.3K</td>
<td>440</td>
<td>198</td>
</tr>
<tr>
<td>VRT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$120.00</td>
<td>$31.4K</td>
<td>22.8K</td>
<td>85</td>
</tr>
<tr>
<td>GEV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/21/25</td>
<td>$500.00</td>
<td>$120.6K</td>
<td>160</td>
<td>80</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding GE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>), we observe a put option sweep with bearish sentiment. It expires in 45 day(s) on August 15, 2025. Parties traded 37 contract(s) at a $250.00 strike. This particular put needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $45.3K, with a price of $1225.0 per contract. There were 1463 open contracts at this strike prior to today, and today 6310 contract(s) were bought and sold. 
• Regarding EMR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>), we observe a put option sweep with bearish sentiment. It expires in 80 day(s) on September 19, 2025. Parties traded 211 contract(s) at a $120.00 strike. This particular put needed to be split into 35 different trades to become filled. The total cost received by the writing party (or parties) was $32.7K, with a price of $155.0 per contract. There were 382 open contracts at this strike prior to today, and today 1617 contract(s) were bought and sold. 
• Regarding BA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>), we observe a call option sweep with bearish sentiment. It expires in 24 day(s) on July 25, 2025. Parties traded 180 contract(s) at a $210.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $118.8K, with a price of $660.0 per contract. There were 847 open contracts at this strike prior to today, and today 1441 contract(s) were bought and sold. 
• For DOV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOV#NYSE">DOV</a>), we notice a call option trade that happens to be bullish, expiring in 45 day(s) on August 15, 2025. This event was a transfer of 118 contract(s) at a $190.00 strike. The total cost received by the writing party (or parties) was $71.9K, with a price of $610.0 per contract. There were 4113 open contracts at this strike prior to today, and today 1011 contract(s) were bought and sold. 
• Regarding FTAI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTAI#NASDAQ">FTAI</a>), we observe a call option sweep with bullish sentiment. It expires in 45 day(s) on August 15, 2025. Parties traded 85 contract(s) at a $130.00 strike. This particular call needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $42.5K, with a price of $500.0 per contract. There were 2452 open contracts at this strike prior to today, and today 914 contract(s) were bought and sold. 
• Regarding PNR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNR#NYSE">PNR</a>), we observe a call option sweep with bullish sentiment. It expires in 45 day(s) on August 15, 2025. Parties traded 500 contract(s) at a $110.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $92.5K, with a price of $185.0 per contract. There were 412 open contracts at this strike prior to today, and today 500 contract(s) were bought and sold. 
• For LYFT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>), we notice a put option sweep that happens to be bullish, expiring in 45 day(s) on August 15, 2025. This event was a transfer of 186 contract(s) at a $16.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $25.1K, with a price of $135.0 per contract. There were 12945 open contracts at this strike prior to today, and today 303 contract(s) were bought and sold. 
• Regarding FDX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>), we observe a call option trade with bearish sentiment. It expires in 80 day(s) on September 19, 2025. Parties traded 191 contract(s) at a $280.00 strike. The total cost received by the writing party (or parties) was $34.3K, with a price of $180.0 per contract. There were 440 open contracts at this strike prior to today, and today 198 contract(s) were bought and sold. 
• For VRT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>), we notice a call option trade that happens to be neutral, expiring in 80 day(s) on September 19, 2025. This event was a transfer of 20 contract(s) at a $120.00 strike. The total cost received by the writing party (or parties) was $31.4K, with a price of $1571.0 per contract. There were 22888 open contracts at this strike prior to today, and today 85 contract(s) were bought and sold. 
• Regarding GEV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>), we observe a call option sweep with neutral sentiment. It expires in 143 day(s) on November 21, 2025. Parties traded 20 contract(s) at a $500.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $120.6K, with a price of $6032.0 per contract. There were 160 open contracts at this strike prior to today, and today 80 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

FTAI

LYFT

10 Industrials Stocks Whale Activity In Today's Session

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Consumer Discretionary sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSLA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/03/25</td>
<td>$300.00</td>
<td>$26.5K</td>
<td>23.2K</td>
<td>78.5K</td>
</tr>
<tr>
<td>AMZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$230.00</td>
<td>$45.2K</td>
<td>18.8K</td>
<td>5.4K</td>
</tr>
<tr>
<td>HAS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$82.50</td>
<td>$256.5K</td>
<td>11</td>
<td>5.2K</td>
</tr>
<tr>
<td>DBI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$3.00</td>
<td>$50.2K</td>
<td>32</td>
<td>2.5K</td>
</tr>
<tr>
<td>XPEV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$24.00</td>
<td>$28.8K</td>
<td>353</td>
<td>2.2K</td>
</tr>
<tr>
<td>WWW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$20.00</td>
<td>$62.7K</td>
<td>5.1K</td>
<td>1.1K</td>
</tr>
<tr>
<td>JD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$33.00</td>
<td>$37.6K</td>
<td>2.2K</td>
<td>994</td>
</tr>
<tr>
<td>CROX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$120.00</td>
<td>$32.2K</td>
<td>618</td>
<td>229</td>
</tr>
<tr>
<td>MCD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$320.00</td>
<td>$26.1K</td>
<td>1.4K</td>
<td>201</td>
</tr>
<tr>
<td>SRM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$7.50</td>
<td>$55.0K</td>
<td>440</td>
<td>200</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding TSLA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), we observe a put option sweep with bearish sentiment. It expires in 2 day(s) on July 3, 2025. Parties traded 40 contract(s) at a $300.00 strike. This particular put needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $26.5K, with a price of $665.0 per contract. There were 23275 open contracts at this strike prior to today, and today 78572 contract(s) were bought and sold. 
• For AMZN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), we notice a call option sweep that happens to be bearish, expiring in 45 day(s) on August 15, 2025. This event was a transfer of 67 contract(s) at a $230.00 strike. This particular call needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $45.2K, with a price of $675.0 per contract. There were 18885 open contracts at this strike prior to today, and today 5482 contract(s) were bought and sold. 
• Regarding HAS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAS#NASDAQ">HAS</a>), we observe a call option trade with bearish sentiment. It expires in 80 day(s) on September 19, 2025. Parties traded 900 contract(s) at a $82.50 strike. The total cost received by the writing party (or parties) was $256.5K, with a price of $285.0 per contract. There were 11 open contracts at this strike prior to today, and today 5247 contract(s) were bought and sold. 
• Regarding DBI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBI#NYSE">DBI</a>), we observe a call option sweep with bearish sentiment. It expires in 45 day(s) on August 15, 2025. Parties traded 2500 contract(s) at a $3.00 strike. This particular call needed to be split into 20 different trades to become filled. The total cost received by the writing party (or parties) was $50.2K, with a price of $20.0 per contract. There were 32 open contracts at this strike prior to today, and today 2502 contract(s) were bought and sold. 
• For XPEV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>), we notice a call option sweep that happens to be bearish, expiring in 108 day(s) on October 17, 2025. This event was a transfer of 300 contract(s) at a $24.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $28.8K, with a price of $96.0 per contract. There were 353 open contracts at this strike prior to today, and today 2279 contract(s) were bought and sold. 
• Regarding WWW (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WWW#NYSE">WWW</a>), we observe a call option sweep with bullish sentiment. It expires in 80 day(s) on September 19, 2025. Parties traded 418 contract(s) at a $20.00 strike. This particular call needed to be split into 13 different trades to become filled. The total cost received by the writing party (or parties) was $62.7K, with a price of $150.0 per contract. There were 5167 open contracts at this strike prior to today, and today 1183 contract(s) were bought and sold. 
• Regarding JD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>), we observe a call option sweep with bullish sentiment. It expires in 45 day(s) on August 15, 2025. Parties traded 200 contract(s) at a $33.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $37.6K, with a price of $188.0 per contract. There were 2272 open contracts at this strike prior to today, and today 994 contract(s) were bought and sold. 
• Regarding CROX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CROX#NASDAQ">CROX</a>), we observe a call option trade with bearish sentiment. It expires in 80 day(s) on September 19, 2025. Parties traded 75 contract(s) at a $120.00 strike. The total cost received by the writing party (or parties) was $32.2K, with a price of $430.0 per contract. There were 618 open contracts at this strike prior to today, and today 229 contract(s) were bought and sold. 
• For MCD (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>), we notice a call option sweep that happens to be bullish, expiring in 80 day(s) on September 19, 2025. This event was a transfer of 82 contract(s) at a $320.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $26.1K, with a price of $320.0 per contract. There were 1478 open contracts at this strike prior to today, and today 201 contract(s) were bought and sold. 
• For SRM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRM#NASDAQ">SRM</a>), we notice a put option trade that happens to be bearish, expiring in 45 day(s) on August 15, 2025. This event was a transfer of 200 contract(s) at a $7.50 strike. The total cost received by the writing party (or parties) was $55.0K, with a price of $275.0 per contract. There were 440 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMZN

CROX

TSLA

XPEV

10 Consumer Discretionary Stocks With Whale Alerts In Today's Session

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVDA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/03/25</td>
<td>$155.00</td>
<td>$140.1K</td>
<td>63.1K</td>
<td>190.6K</td>
</tr>
<tr>
<td>AAPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/03/25</td>
<td>$207.50</td>
<td>$44.8K</td>
<td>22.8K</td>
<td>104.9K</td>
</tr>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/03/25</td>
<td>$130.00</td>
<td>$25.7K</td>
<td>2.7K</td>
<td>14.7K</td>
</tr>
<tr>
<td>MSTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/03/25</td>
<td>$410.00</td>
<td>$98.7K</td>
<td>12.8K</td>
<td>12.4K</td>
</tr>
<tr>
<td>QCOM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/11/25</td>
<td>$162.50</td>
<td>$195.0K</td>
<td>455</td>
<td>4.3K</td>
</tr>
<tr>
<td>BBAI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$8.00</td>
<td>$120.2K</td>
<td>3.9K</td>
<td>2.7K</td>
</tr>
<tr>
<td>INTC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$30.00</td>
<td>$275.2K</td>
<td>20.1K</td>
<td>2.5K</td>
</tr>
<tr>
<td>MSFT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$400.00</td>
<td>$86.2K</td>
<td>3.3K</td>
<td>1.7K</td>
</tr>
<tr>
<td>CSCO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$70.00</td>
<td>$476.0K</td>
<td>1.4K</td>
<td>562</td>
</tr>
<tr>
<td>SOUN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/03/25</td>
<td>$9.50</td>
<td>$33.2K</td>
<td>1.1K</td>
<td>470</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For NVDA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), we notice a call option sweep that happens to be bearish, expiring in 2 day(s) on July 3, 2025. This event was a transfer of 1000 contract(s) at a $155.00 strike. This particular call needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $140.1K, with a price of $140.0 per contract. There were 63157 open contracts at this strike prior to today, and today 190687 contract(s) were bought and sold. 
• For AAPL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), we notice a call option sweep that happens to be bearish, expiring in 2 day(s) on July 3, 2025. This event was a transfer of 200 contract(s) at a $207.50 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $44.8K, with a price of $224.0 per contract. There were 22865 open contracts at this strike prior to today, and today 104991 contract(s) were bought and sold. 
• Regarding PLTR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), we observe a call option sweep with bullish sentiment. It expires in 2 day(s) on July 3, 2025. Parties traded 100 contract(s) at a $130.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $25.7K, with a price of $257.0 per contract. There were 2792 open contracts at this strike prior to today, and today 14750 contract(s) were bought and sold. 
• Regarding MSTR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), we observe a call option sweep with bullish sentiment. It expires in 2 day(s) on July 3, 2025. Parties traded 2759 contract(s) at a $410.00 strike. This particular call needed to be split into 125 different trades to become filled. The total cost received by the writing party (or parties) was $98.7K, with a price of $36.0 per contract. There were 12819 open contracts at this strike prior to today, and today 12441 contract(s) were bought and sold. 
• For QCOM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>), we notice a call option trade that happens to be bearish, expiring in 10 day(s) on July 11, 2025. This event was a transfer of 1000 contract(s) at a $162.50 strike. The total cost received by the writing party (or parties) was $195.0K, with a price of $195.0 per contract. There were 455 open contracts at this strike prior to today, and today 4330 contract(s) were bought and sold. 
• For BBAI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>), we notice a call option trade that happens to be bearish, expiring in 199 day(s) on January 16, 2026. This event was a transfer of 650 contract(s) at a $8.00 strike. The total cost received by the writing party (or parties) was $120.2K, with a price of $185.0 per contract. There were 3934 open contracts at this strike prior to today, and today 2763 contract(s) were bought and sold. 
• For INTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>), we notice a call option sweep that happens to be bearish, expiring in 171 day(s) on December 19, 2025. This event was a transfer of 2500 contract(s) at a $30.00 strike. This particular call needed to be split into 31 different trades to become filled. The total cost received by the writing party (or parties) was $275.2K, with a price of $110.0 per contract. There were 20126 open contracts at this strike prior to today, and today 2536 contract(s) were bought and sold. 
• Regarding MSFT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), we observe a call option sweep with bearish sentiment. It expires in 199 day(s) on January 16, 2026. Parties traded 8 contract(s) at a $400.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $86.2K, with a price of $10786.0 per contract. There were 3382 open contracts at this strike prior to today, and today 1716 contract(s) were bought and sold. 
• Regarding CSCO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>), we observe a call option sweep with bullish sentiment. It expires in 563 day(s) on January 15, 2027. Parties traded 560 contract(s) at a $70.00 strike. This particular call needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $476.0K, with a price of $850.0 per contract. There were 1464 open contracts at this strike prior to today, and today 562 contract(s) were bought and sold. 
• For SOUN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>), we notice a call option trade that happens to be bearish, expiring in 2 day(s) on July 3, 2025. This event was a transfer of 400 contract(s) at a $9.50 strike. The total cost received by the writing party (or parties) was $33.2K, with a price of $83.0 per contract. There were 1150 open contracts at this strike prior to today, and today 470 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AAPL

BBAI

CSCO

INTC

MSFT

MSTR

NVDA

PLTR

QCOM

SOUN

10 Information Technology Stocks Whale Activity In Today's Session

As Wall Street moves more and more into the retail crowd&#8217;s high-conviction, high-volatility trade appetites, Defiance ETFs is pushing it one step further: abandoning the basket and going straight for the bulls — and the bears. 
Its latest creation is <a href="https://www.benzinga.com/etfs/new-etfs/25/06/46076082/new-defiance-etfs-offer-2x-bull-and-bear-exposure-to-ionq-oklo-and-soundhound-ai">a series of single-stock leveraged ETFs</a> that hone in on some of the riskiest, most speculative areas of the market: quantum computing, voice AI and next-gen nuclear power.
In an interview with Benzinga, Defiance ETFs CEO Sylvia Jablonski explained the reasoning behind this lineup — Defiance Daily Target 2X Short IONQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONZ#NASDAQ">IONZ</a>), Defiance Daily Target 2X Long OKLO ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKLL#NASDAQ">OKLL</a>) and Defiance Daily Target 2X Long SOUN ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUX#NASDAQ">SOUX</a>) — why she&#8217;s risking it all on early-stage innovation names and what retail traders need to know before diving into these <a href="https://www.benzinga.com/etfs">hotshot funds</a>.

<h1 class="wp-block-heading">Why These Names — And Why Now?</h1>
The new ETFs provide 2X daily long and short exposure to three budding technology firms: IonQ Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>), a leader in quantum computing; SoundHound AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>), a voice AI solutions company and Oklo Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>), a firm that specializes in designing small nuclear fission reactors.
As defined by Jablonski, the unifying thread is straightforward: &#8220;We selected these names because each represents a disruptive, early-stage technology with the potential to reshape major industries — nuclear energy, AI and quantum computing. These are high-conviction, high-volatility stories that align well with the goals of tactical traders seeking targeted exposure through 2X daily leverage.&#8221;
That is to say, they&#8217;re bespoke for individual investors who don&#8217;t wish to bet broadly, they wish to bet large and specifically.
<h1 class="wp-block-heading">Betting On A Nuclear Future</h1>
Of the three, Oklo is arguably the riskiest move — pre-revenue still, new to the public through SPAC, as well as in an industry long beset by regulatory challenges and public distrust. Yet Jablonski has a different perspective.
&#8220;Oklo is pioneering next-gen nuclear fission with compact reactors designed for modern energy needs,&#8221; Jablonski replied, citing the company&#8217;s progress towards licensure, power purchase agreements, and endorsements from prominent supporters like Sam Altman.
Its volatility and binary milestone-based narrative render it &#8220;well-suited for a leveraged ETF structure,&#8221; particularly in a time when nuclear is receiving renewed attention due to the global energy crisis, decarbonization initiatives, and bipartisan political backing.
&#8220;Oklo is one of the most advanced players in the small modular reactor space. Its design is scalable, efficient, and aimed at off-grid and decentralized use cases,&#8221; Defiance said. &#8220;It's positioned as a first mover in what we see as a major inflection point for clean, dispatchable energy.&#8221;
<h1 class="wp-block-heading">Quantum And AI: Big Tech&#8217;s Next Bets</h1>
At the other end of the speculative spectrum are IonQ and SoundHound AI, two firms banking on longer-term, but fast-converging, tech megatrends.
With IonQ, Defiance is providing what it deems the &#8220;Nvidia of quantum,&#8221; a public pure-play in a space with increasing institutional demand and deep-pocketed deals. 
&#8220;IonQ is the first publicly traded pure-play quantum computing company and a leader in trapped-ion hardware. It has strong commercial partnerships, growing revenue, and institutional support. IONZ provides a direct, amplified way to trade this frontier technology as it moves from lab to real-world applications. The company has relationships with the top MAG7 tech leaders as well, an integration with that crowd could propel opportunities,&#8221; Jablonski said.
With SoundHound, she sees voice AI as an emerging layer in industries as diverse as auto to customer service. 
&#8220;Quantum and voice AI could change the face and revenues of many industries in the future. Soundhound for example, could change the way that we experience customer service — clients like Mercedes Benz and Honda have taken note,&#8221; Jablonski said. &#8220;With quantum, we are talking about a multi-trillion-dollar industry, in its infancy.&#8221;
<h1 class="wp-block-heading">Accuracy Over Baskets</h1>
Defiance&#8217;s new offerings also indicate a change in behavior among retail investors. While thematic ETFs swelled in popularity during the past decade, many investors now desire greater control and more intensity.
&#8220;Traders want precision,&#8221; Defiance ETFs stated. &#8220;Many are moving away from broad thematic ETFs in favor of single-stock strategies that let them express specific views. These products allow investors to lean into the individual stories they follow closely and believe in.&#8221;
And while daily leveraged ETFs aren't new, applying them to disruptive early-stage names marks a new chapter, one that comes with serious risk. Defiance isn't shying away from that, instead emphasizing that these are tactical tools, not long-term investments.
"We're transparent that these are tactical trading tools. The daily reset structure is clearly disclosed, and we emphasize investor education," said Jablonksi. "We design these products for traders who understand the risk-reward dynamics of short-term, leveraged exposure."
<h1 class="wp-block-heading">Competition Heats Up In Quantum</h1>
The timing of Defiance&#8217;s quantum play is also coinciding with <a href="https://www.benzinga.com/etfs/new-etfs/25/06/46080190/quantum-volatility-tradrs-new-etfs-qubx-rgtu-are-built-for-it-says-matt-markiewicz">the recent launch</a> by Tradr of its 2X Long QBTS Daily ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/QUBX#BATS">QUBX</a>), an ETF dedicated to Quantum Computing Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>). While Defiance is taking a single-stock, leveraged approach, QUBX provides exposure to a smaller quantum company.
&#8220;IONQ is the Nvidia of AI, QUBX gives exposure to a smaller up and comer,&#8221; Defiance ETFs said. &#8220;Both are a testament to the interest in trading the quantum theme.&#8221;
In short, the ETF race to the future of computing has started.
<h1 class="wp-block-heading">Final Thoughts</h1>
From atomic to artificial brains, Defiance&#8217;s new ETFs are wagering that individual traders need more than market-cap-weighted exposure. They need access to the next phenomenon, with leverage.
Whether these products ignite a new era of retail trading innovation or are too unstable to manage remains to be seen.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46193784/d-wave-quantum-stock-is-trading-higher-tuesday-whats-happening">D-Wave Quantum Stock Is Trading Higher Tuesday: What&#8217;s Happening?</a></li>
</ul>
Photo: Shutterstock

Sector ETFs

New ETFs

Exclusives

Trading Ideas

Interview

ETFs

IONQ

IONZ

OKLL

OKLO

QUBT

QUBX

SOUX

Quantum, AI, Nuclear: Three Frontiers, One Launchpad Powered By Defiance ETFs

Roth Capital analyst Joe Reagor reiterates Silvercorp Metals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SVM#AMEX">SVM</a>) with a Buy and raises the price target from $6.25 to $6.75.

Roth Capital Reiterates Buy on Silvercorp Metals, Raises Price Target to $6.75

Roth Capital analyst Joe Reagor reiterates McEwen Mining (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUX#NYSE">MUX</a>) with a Buy and raises the price target from $12 to $15.

Roth Capital Reiterates Buy on McEwen Mining, Raises Price Target to $15

Avadel Pharmaceuticals Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDL#NASDAQ">AVDL</a>) is under fire from its shareholder ASL Strategic Value Fund, LP, which is pushing for a complete overhaul of the board following what it describes as a series of strategic failures tied to Lumryz, the company&#8217;s <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">once-nightly narcolepsy treatment</a>.
In a letter released Monday, ASL argued Avadel failed to capitalize on Lumryz&#8217;s market potential, costing the company hundreds of millions in revenue and <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b46164920/asl-strategic-value-fund-issues-open-letter-to-avadel-shareholders" rel="noreferrer noopener">diminishing shareholder value</a>.
ASL, which holds approximately $15 million in Avadel stock, criticized the company&#8217;s slow patient conversion from Jazz Pharmaceutical Plc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) Xyrem to Lumryz, despite the latter having been deemed &#8220;clinically superior&#8221; by the FDA.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/42891870/avadel-pharmaceuticals-misses-earnings-estimate-but-posts-150-increase-in-sales-from-its-narcolepsy-drug-lumryz" rel="noreferrer noopener">Avadel Pharmaceuticals Misses Earnings Estimates But Posts 150% Sales Increase From Narcolepsy Drug LUMRYZ</a>
Since Lumryz&#8217;s approval in 2021, only about 1,000 patients have made the switch, which ASL estimates represents a $600 million to $800 million shortfall.
The group called this delay in targeting Xyrem patients a &#8220;strategic blunder,&#8221; claiming it has shaved $5 to $7 per share from shareholder value.
The fund is urging shareholders to vote out the current board at the July 29 annual meeting. It is pressing Avadel to engage an investment bank to evaluate options for monetizing Lumryz.
This includes exploring partnerships or licensing deals, particularly given its recent Orphan Drug Designation for idiopathic hypersomnia (IH), a move that could generate an additional $500 million to $1 billion in annual revenue if Lumryz is approved for the rare sleep disorder.
Avadel defended its strategy, saying it is actively working with major shareholders and remains committed to unlocking Lumryz&#8217;s full value.
The company also highlighted a recent legal win in which a U.S. court affirmed the FDA&#8217;s conclusion that Lumryz&#8217;s once-nightly dosing is clinically superior to its competitors. However, ASL pointed to ongoing litigation with Jazz Pharmaceuticals, six lawsuits in total, as another area where the board has underdelivered.
With one case heading to trial within four months and over $1 billion at stake, ASL accuses leadership of failing to act urgently or communicate the opportunity to investors.
Beyond strategic concerns, ASL cited governance issues, including uncounted shareholder votes and a lack of transparency around executive pay.
Despite Avadel&#8217;s falling market capitalization, from $2.5 billion to $900 million over two years, CEO compensation was $7.4 million in 2024, raising further concerns over accountability.
On Friday, Avadel Pharmaceuticals said the U.S. Court of Appeals for the D.C. Circuit upheld a lower court&#8217;s decision siding with the U.S. Food and Drug Administration (FDA) in a case <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g46164897/avadel-pharmaceuticals-announces-unanimous-appeals-court-decision-upholding-fda-approval-of-lumryz" rel="noreferrer noopener">brought by Jazz Pharmaceuticals</a>.
Earlier in June, the FDA granted Orphan Drug Designation to Lumryz for <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45789373/avadel-pharmaceuticals-receives-orphan-drug-designation-from-fda-for-lumryz-sodium-oxybate-for-ext" rel="noreferrer noopener">Idiopathic Hypersomnia</a>.
Price Action: AVDL stock is trading lower by 0.40% to $8.83 at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46199715/warner-bros-discovery-wbd-stock-slides-on-major-stake-sale" target="_blank" rel="noreferrer noopener">Warner Bros. Discovery (WBD) Stock Slides On Major Stake Sale</a></li>
</ul>
Photo by Gorodenkoff via Shutterstock

Biotech

General

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

JAZZ

Avadel Shareholder Seeks Board Shakeup, Citing Millions Lost On Lumryz

LIXT

Lixte Biotechnology Granted U.S. Patent #12343342: Methods For Treating Soft Tissue Sarcoma

Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) price may continue to stay within its <a href="https://www.benzinga.com/money/bitcoin-price-prediction">current trading range</a> despite rising institutional interest and significant ETF inflows, according to Michael Bucella, managing partner at Neoclassic Capital.
In an <a href="https://www.youtube.com/watch?v=j09LmitdAL4">interview</a> with CNBC on Tuesday, Bucella explained that although demand for Bitcoin is strong, structural factors are preventing further price movement.
&#8220;ETF inflows have been enormous, I think $4 billion in June alone,&#8221; Bucella said, highlighting the surge of institutional capital entering Bitcoin through regulated products. 
However, he pointed out that this demand is not directly translating into higher prices.
Bucella said that some investors are rotating out of Bitcoin spot positions and into crypto-related equities like Coinbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>), Circle (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDC</a>), and Bitcoin treasury companies, shifting how they gain exposure to the asset class. 
&#8220;There&#8217;s people replacing Bitcoin spot risk with Circle or Coinbase or treasury companies,&#8221; he noted.
One of the key supply-side pressures, according to Bucella, comes from Bitcoin miners who are now operating on increasingly narrow margins. 
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46174956/solana-etf-approval-imminent-as-odds-skyrocket-to-97">Solana ETF Approval Imminent As Odds Skyrocket To 97%</a>
&#8220;If you don&#8217;t have highly credible, high top assets with great operating teams to pivot to at least attempt to get an AI contract or a hyperscaler contract, you have to sort of run these sometimes loss operating models,&#8221; Bucella said. 
He added that this is leading some miners to sell Bitcoin to sustain their operations.
Despite Bitcoin&#8217;s year-to-date gains of approximately 15%, Bucella noted that the asset's performance has not aligned with the strength seen in broader equity markets. 
&#8220;It is a bit surprising to have seen the price of Bitcoin stay stuck in this sort of range,&#8221; he said.
Why It Matters: Bucella also commented on Bitcoin's behavior during recent geopolitical tensions.
During the Israel-Iran conflict escalation, Bitcoin sold off, showing that it continues to behave like a risk asset rather than acting as a defensive hedge. 
&#8220;If it&#8217;s not going to [act like digital gold], to me, its most valuable kind of selling point is when it acts like digital gold,&#8221; Bucella said.
Looking at the broader market, Bucella observed that demand remains strong for Bitcoin treasury companies, but smaller firms may need to develop more diversified models beyond simply holding Bitcoin to remain attractive to investors.
He also commented on Circle's valuation surge following its IPO, suggesting that the company's potential to reshape payment systems, rather than simply its stablecoin issuance, may be what investors are focusing on. 
&#8220;What Circle represents is potentially destabilizing the traditional payments and traditional capital markets rails,&#8221; Bucella said.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46173137/the-investment-rule-ric-edelman-just-threw-out-and-what-he-replaced-it-with">The Investment Rule Ric Edelman Just Threw Out—And What He Replaced It With</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$USDC

COIN

Why Bitcoin Is Trapped In A Range Despite Record ETF, Treasury Company Flows

WIIM

WETO

WETO stock has given up its prior gain. Webus International shares were trading higher after the company announced it secured up to $100 million in equity financing with Ripple Strategy Holdings.

Asset Sales

Sturm Ruger Announces Asset Purchase Of Anderson Manufacturing: Terms Not Disclosed

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fthearenagroup.net%2F&amp;esheet=54284886&amp;newsitemid=20250701744150&amp;lan=en-US&amp;anchor=The+Arena+Group+Holdings%2C+Inc.&amp;index=1&amp;md5=5948f435552dffedd66c9e29d573ae2c">The Arena Group Holdings, Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AREN#NYSE">AREN</a>) ("Arena"), a technology platform and media company home to hundreds of media brands, including TheStreet, Parade, Men's Journal, Athlon Sports, Surfer, Powder and more, today announced it has been added as a member of the Russell 2000&#xAE; Index, effective as of June 30, 2025 as part of the 2025 Russell U.S. Indexes reconstitution.
Membership in the Russell 2000&#xAE; Index reflects inclusion in the broader Russell 3000&#xAE; Index, which captures the 4,000 largest U.S. stocks as of April 30, ranking them by total market capitalization. Companies are also included in the appropriate growth and value style indexes as well. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

AREN

Arena Group Holdings Added To Russell 2000 Index, Signaling Broader Russell 3000 Index Inclusion

Roth Capital analyst Joe Reagor maintains MAG Silver (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MAG#AMEX">MAG</a>) with a Neutral and raises the price target from $18 to $21.

Roth Capital Maintains Neutral on MAG Silver, Raises Price Target to $21

If you've ever wished there was a simple way to enjoy pure, mineral-rich water and freshly brewed coffee without the hassle of refills, plumbing hookups, or endless plastic waste, you're down to your final chance to make it happen. Kara Pod — the world's first self-refilling coffee machine that generates clean drinking water straight from the air — is almost at the finish line of its Kickstarter campaign. Early supporters<a href="https://www.kickstarter.com/projects/karawater/karapod?ref=48p363"> have less than 25 hours left to lock in exclusive savings that won't be offered again</a>, with discounts reaching up to $340 off the expected retail price. Whether you live in a small apartment, an off-grid cabin, or a busy family home, Kara Pod offers a way to drink better without compromise, and time to secure yours is almost up.
<h2 class="wp-block-heading">What Makes Kara Pod Different?</h2>
At first glance, <a href="https://www.kickstarter.com/projects/karawater/karapod?ref=48p363">Kara Pod</a> looks like a sleek countertop coffee machine. But inside, it's doing something remarkable. Instead of requiring a plumbing connection or water deliveries, Kara Pod draws moisture directly from the surrounding air. Using advanced filtration and purification, it transforms that humidity into fresh, alkaline water you can drink immediately or use to brew coffee. Every drop passes through a multi-stage process that includes dual UV sterilization, a carbon filter, and final mineralization, so you end up with clean, great-tasting water enhanced with calcium, magnesium, and sodium. The internal 3.2-liter tank holds enough for about seven bottles of water or up to eighteen cups of coffee each day, and because everything is automated, you never have to refill a jug or connect a hose — just plug it in and let it get to work.
<h2 class="wp-block-heading">Coffee and Hydration in One Appliance</h2>
Beyond its water-generating abilities, Kara Pod is also a full-featured coffee maker designed to deliver a barista-quality experience. It's compatible with both Kara's own compostable coffee pods and Nespresso Original Pods, so you can choose your preferred blend or roast. Unlike many all-in-one machines, Kara Pod has separate dispensing nozzles — one dedicated to water, the other to coffee — so there's no crossover of flavors or residues. Through the touchscreen, you can customize cup size, adjust coffee strength, and save your favorite settings. That means you can pour a glass of fresh mineral water and then immediately brew an espresso without swapping tanks or cleaning components in between. It's an unusually thoughtful design for anyone who wants both hydration and high-quality coffee without cluttering the kitchen.
<h2 class="wp-block-heading">No Refills, No Plumbing, No Plastic Waste</h2>
A big reason so many people have backed Kara Pod is how effortless it is to operate. There's no need for bottled water, no expensive delivery contracts, and no refilling a reservoir every day. Kara Pod simply creates water as you need it, drawing from the air in your kitchen or workspace. Because it runs on standard power outlets — either 110V or 220V — it works almost anywhere. This design doesn't just save you time; it also significantly reduces your environmental footprint. You won't be throwing away single-use plastic bottles, hauling delivery jugs, or creating unnecessary waste. Even the coffee pods are compostable.
<h2 class="wp-block-heading">Technical Details at a Glance</h2>
While Kara Pod is compact, it's packed with capability. The machine measures roughly 15 inches by 9 inches by 14 inches — comparable in size to a Keurig K-Select — and weighs about 13 pounds. It has a storage capacity of 3.2 liters, enough for daily use by singles, couples, or small families. The power consumption is 270 watts, and the voltage range is fully compatible with both US and international outlets. All controls are handled through an intuitive touchscreen that walks you through setup, customization, and maintenance reminders.
<h2 class="wp-block-heading">Who Is Kara Pod Designed For?</h2>
Kara Pod is an easy fit for a wide range of people and spaces. If you live in an apartment where tap water is unreliable or tastes unpleasant, Kara Pod gives you a consistent source of mineral-rich water without plumbing. For off-grid living, RV trips, or cabins where running water isn't practical, it offers a self-sufficient hydration solution. Families looking to cut back on plastic waste will appreciate how it replaces bottled water entirely, while small offices and workspaces can use it to provide healthier, hassle-free drinks throughout the day. Essentially, anyone who wants clean water and quality coffee, anywhere, will find Kara Pod surprisingly versatile.
<h2 class="wp-block-heading">Kickstarter Pricing and Rewards</h2>
During this final stretch of the campaign, backers can still claim significant savings. A <a href="https://www.kickstarter.com/projects/karawater/karapod?ref=48p363">single Kara Pod is available starting from $459</a>, which represents up to $340 off the estimated retail price. There are also bundled options — like a single unit plus extra filter sets for longer-term use, starting around $477, or multi-unit packages ideal for gifting or outfitting multiple rooms. Shipping costs will be calculated after the campaign wraps up, and you can view estimated rates directly on the Kickstarter page. Given how quickly the campaign is closing, many reward tiers are almost sold out.
<h2 class="wp-block-heading">Why Back Kara Pod Before Time Runs Out?</h2>
Backing Kara Pod now isn't just about getting the best price. Early backers play a pivotal role in making this new category of appliance widely available. The project is structured as all-or-nothing — if it doesn't hit the funding goal by Wednesday, July 2, 2025, at 6:45 AM (Pacific), production won't proceed and your card won't be charged. Already, hundreds of backers have pledged support and shared feedback, with a lively comment section and transparent updates from the creators. If you've been considering it, this is the moment to act.
<h2 class="wp-block-heading">How to Reserve Your Kara Pod</h2>
There are only hours left to secure your Kara Pod and start transforming how you drink water and coffee every day. Backing is simple: just visit the Kickstarter page, choose your reward, and complete your pledge before the campaign closes. After that, these early-backer discounts will disappear, and you'll have to wait for retail availability at full price. Invest now with as little a $1, or <a href="https://www.kickstarter.com/projects/karawater/karapod?ref=48p363">invest $459 to get a Kara Pod</a> (at a discount of 43% off its retail price). No refills. No plumbing. No plastic. Just a better way to stay hydrated—and you have less than 25 hours to claim it.

Tech

Only 25 Hours Left: Back Kara Pod and Invest Early in the Future of Air-to-Water Tech

Roth Capital analyst Joe Reagor reiterates Coeur Mining (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CDE#NYSE">CDE</a>) with a Buy and raises the price target from $10 to $12.

Roth Capital Reiterates Buy on Coeur Mining, Raises Price Target to $12

Jumia Technologies AG &#8211; ADR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JMIA#NYSE">JMIA</a>) shares are trading higher Tuesday afternoon as the company becomes the subject of takeover interest from Axian Telecom, per a Bloomberg <a href="https://www.bloomberg.com/news/articles/2025-07-01/e-commerce-firm-jumia-said-to-draw-takeover-interest-from-axian">report</a>.
What To Know: Axian Telecom recently raised $600 million in financing, according to sources who spoke with Bloomberg. These funds are intended to refinance existing debt and strategically position the company for a possible acquisition of Jumia. Deliberations are <a href="https://www.bloomberg.com/news/articles/2025-07-01/e-commerce-firm-jumia-said-to-draw-takeover-interest-from-axian">reportedly</a> ongoing and private, with no definitive agreement reached, per Bloomberg.
This potential merger follows Axian&#8217;s disclosure in May of an 8% stake in Jumia. Such an acquisition could create a powerful synergy, combining Axian&#8217;s telecommunications infrastructure with Jumia&#8217;s established e-commerce network. Representatives for both Jumia and Axian have declined to comment to Bloomberg on the speculation.
What Else: Jumia is a leading <a href="https://www.benzinga.com/topic/e-commerce">e-commerce</a> platform in Africa, often called the &#8220;Amazon of Africa.&#8221; It provides a marketplace for consumers to buy a wide range of products, a logistics service for delivery and a payment platform, JumiaPay.
News of a potential takeover by Axian Telecom would likely cause Jumia&#8217;s stock to rise for a key reason: acquisition premium. Typically, a company seeking to acquire another offers to buy its shares at a price higher than the current market value. 
The prospect of this higher payout makes the stock more attractive, driving up its price as investors anticipate the potential acquisition.
Price Action: According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, JMIA shares are trading higher by 16.5% to $4.67. JMIA has a 52-week high of $15.04 and a 52-week low of $1.60.
Read Also: <a href="https://www.benzinga.com/pressreleases/25/06/ac46181754/jumia-opens-new-warehouse-in-egypt-to-boost-logistics-job-creation-and-digital-economy">Jumia Opens New Warehouse in Egypt to Boost Logistics, Job Creation, and Digital Economy</a>
<h2 class="wp-block-heading">How To Buy JMIA Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Jumia Technologies&#8217; case, it is in the Consumer Discretionary sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.

JMIA

Jumia (JMIA) Stock Surges On Axian Takeover Buzz: What Investors Need To Know

Roth Capital analyst Joe Reagor maintains Anglogold Ashanti (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AU#NYSE">AU</a>) with a Buy and raises the price target from $52 to $54.

Roth Capital Maintains Buy on Anglogold Ashanti, Raises Price Target to $54

Roth Capital analyst Joe Reagor downgrades Avino Silver &amp; Gold Mines (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ASM#AMEX">ASM</a>) from Buy to Neutral and raises the price target from $2.75 to $3.5.

Downgrades

Roth Capital Downgrades Avino Silver & Gold Mines to Neutral, Raises Price Target to $3.5

지난주 도널드 트럼프 대통령이 약가 인하 <a href="https://www.benzinga.com/general/health-care/25/05/45384935/trump-again-promises-lower-drug-prices-by-cutting-out-middlemen-like-unitedhealth-cvs-will-it-work-this-time" target="_blank" rel="noopener">행정명령</a>에 서명한 후, 전문가들은 제약사들이 가격 결정력이 떨어지는 가운데 마진 축소 가능성에 직면해 있는 가운데 처방약급여관리업체(PBM)가 가장 큰 타격을 받을 수 있다.
무슨 일 있었나: LPL 파이낸셜의 주식 리서치 책임자 토마스 쉽은 <a href="https://www.benzinga.com/news/25/05/45389750/trump-claims-drug-price-crackdown-could-slash-your-prescription-costs-by-59-but-will-big-pharma-fight-it-again" target="_blank" rel="noopener">제약사</a>들이 국내에서 가격 인하 압력에 직면하고 있다며, "가격 결정력을 약화시켜 마진을 압박할 가능성이 있으며, 제약사 주가에 상당한 역풍을 제공할 것"이라고 말했다.
그러나 그는 의약품 유통을 촉진하고 제약사와 협상을 통해 처방 비용을 낮추는 "중간자" 또는 PBM이 제약사로부터 리베이트를 받거나 "스프레드 프라이싱"과 같은 불투명한 가격 책정 관행으로 인해 조사를 받고 있다고 설명한다.
"PBM은 약국에 건강보험 가입자에게 청구하는 약값보다 적은 금액을 지불한다.&#8221;
트럼프가 서명한 또 다른 4월 15일 <a href="https://www.benzinga.com/markets/25/04/44866755/mark-cuban-says-this-trump-healthcare-order-could-save-hundreds-of-billions" target="_blank" rel="noopener">행정명령</a>은 PBM 수수료에 대한 투명성 강화를 촉구하고 이러한 중개업체의 역할을 재평가할 것을 요구했다.
CVS헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), 시그나 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), 유나이티드헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)가 가장 큰 규모의 PBM 회사들이다.
또한 토마스 쉽은 PBM 비용 절감은 예상되지만 직접적인 가격 통제는 미국 중심의 제약사에게 장기적인 위험을 초래할 수 있다고 강조했다. 그는 투명성을 통해 PBM 마진 침식이 제조업체의 더 큰 가격 인하를 막을 수 있는지 여부를 알 수 있을 것이라고 했다.
"이러한 행정명령이 어떻게 시행될지에 대해서는 많은 의문이 남아 있지만, 초기 뉴스 흐름이 소화되고 나면 그 순효과는 PBM보다는 제약사에 덜 해로운 것으로 보인다.&#8221;
"그렇긴 하지만 미국인들이 의약품을 구매하는 방식을 바꾸는 데는 오랜 시간이 걸릴 것이다. 그 과정에서 소비자 직접 판매를 지원하려는 노력은 이를 주도하는 제조사와 유통을 위해 협력하는 제조사 모두를 지원할 것이다.&#8221;
왜 중요한가: 한편, 억만장자 투자자이자 &#8216;샤크 탱크&#8217;로 유명한 마크 큐반은 <a href="https://www.benzinga.com/personal-finance/25/04/44674382/mark-cuban-says-big-insurance-companies-and-pbms-control-healthcare-costs-everyone-has-to-kiss-their-a-and-accept-the-complications" target="_blank" rel="noopener">가격이 아닌 리베이트를 협상한다</a>고 설명하면서 엑스(X) 게시물에서 PBM을 "부정한 돈벌이"라고 불렀다.
"그들은 리베이트를 협상한다. 가격이 아니라 리베이트를 협상하는 것이다. 실제로 대형 PBM이 리베이트 협상의 95퍼센트 이상을 통제하고 있다. 대형 브랜드 제약사는 다른 제약사와 협상할 수 없다. 내 생각에 그것은 부정한 돈벌이다.&#8221;
4월 15일의 명령은 가격 책정의 투명성을 요구하지만, 큐반은 4조 9천억 달러에 달하는 의료비 지출의 30%가 대형 PBM이 만들어내는 가격 왜곡과 간접 보험회사에 기인한다고 강조한다.
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
One of the great lies the big PBM industry tells us is that they are needed to negotiate lower prices. 
It&#39;s a lie. They negotiate rebates. Not prices. In fact, the big PBMs control more than 95pct of the rebate negotiations. Big brand Pharma companies can&#39;t negotiate with…
&mdash; Mark Cuban (@mcuban) <a href="https://twitter.com/mcuban/status/1923880717420986860?ref_src=twsrc%5Etfw">May 17, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
2025년에 성과를 낸 위의 PBM 운영 회사는 다음과 같다.
<figure class="wp-block-table is-style-stripes">
<table class="has-fixed-layout">
<tbody>
<tr>
<td>주식</td>
<td>연초 대비 성과</td>
<td>1년 성과</td>
</tr>
<tr>
<td>CVS헬스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</td>
<td>41.41%</td>
<td>8.94%</td>
</tr>
<tr>
<td>시그나 그룹 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>)</td>
<td>16.92%</td>
<td>-3.73%</td>
</tr>
<tr>
<td>유나이티드헬스 그룹 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)</td>
<td>-42.14%</td>
<td>-43.56%</td>
</tr>
</tbody>
</table>
</figure>
투자자들이 고려할 수 있는 몇 가지 제약 관련 ETF는 다음과 같다.
<figure class="wp-block-table is-style-stripes">
<table class="has-fixed-layout">
<tbody>
<tr>
<td>제약 ETF</td>
<td>연초 대비 성과</td>
<td>1년 성과</td>
</tr>
<tr>
<td>VanEck Pharmaceutical ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPH#NASDAQ">PPH</a>)</td>
<td>-0.28%</td>
<td>-4.66%</td>
</tr>
<tr>
<td>iShares US Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)</td>
<td>-1.20%</td>
<td>-2.03%</td>
</tr>
<tr>
<td>Invesco Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJP#NYSE">PJP</a>)</td>
<td>-3.45%</td>
<td>-0.83%</td>
</tr>
<tr>
<td>SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>)</td>
<td>-4.83%</td>
<td>-1.70%</td>
</tr>
<tr>
<td>KraneShares MSCI All China Health Care Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KURE#NYSE">KURE</a>)</td>
<td>11.10%</td>
<td>1.65%</td>
</tr>
<tr>
<td>First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXH#NASDAQ">FTXH</a>)</td>
<td>-6.51%</td>
<td>-6.89%</td>
</tr>
<tr>
<td>Direxion Daily Pharmaceutical &amp; Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PILL#NYSE">PILL</a>)</td>
<td>-23.63%</td>
<td>-24.07%</td>
</tr>
</tbody>
</table>
</figure>
SPDR S&amp;P 500 ETF 트러스트 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)와 인베스코 QQQ 트러스트 ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)는 각각 S&amp;P 500 지수와 나스닥 100 지수를 추적하며 지난 금요일에 상승 마감했다. SPY는 0.63% 상승하여 594.20달러, QQQ는 0.44% 상승하여 521.51달러에 마감했다.
사진 제공: Rawpixel.com / Shutterstock.com
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

도널드 트럼프 대통령은 수요일(9일) 상호관세를 90일 동안 일시 중단했지만, 나중에 집무실에서 기자들과의 대화에서 제약 회사들이 관세에 직면할 것이라고 확인했다.
무슨 일 있었나: 제약주 랠리는 목요일 시장이 하락세로 전환되면서 단기간에 그쳤다. 한 기자가 트럼프 대통령에게 제약 주식에 관세를 부과할 것이냐는 질문을 하자, 트럼프 대통령은 이렇게 답했다. "그렇게 할 것이다. 왜냐하면 우리는 그들이 다시 돌아오기를 원하기 때문이다.&#8221;
"코로나19를 겪으면서 우리는 미국에서 의약품을 만들지 않는다는 사실을 깨달았다. 그래서 큰 깨달음을 얻었다.&#8221;
트럼프는 코로나19의 비상 사태를 언급하며 제약 회사들이 미국에서 의약품을 생산하기를 원한다고 말했다.
"우리는 약을 구하기 위해 중국으로 가야 했고, 다른 곳으로 가야 했고, 약을 구하지 못했다. 우리가 그들이 떠나도록 내버려 두었기 때문이다&#8230;제약 회사에 관세를 부과할 것이고, 모두 돌아오고 싶어 할 것이다.&#8221;
트럼프의 관세 확정 이후 목요일 제약주는 급락했다.
<figure class="wp-block-table is-style-stripes">
<table style="overflow:auto; height: 90px; display: block;">
<tbody>
<tr>
<td>제약주</td>
<td>목요일 주가 변동</td>
<td>2025년 변동</td>
<td>지난 1년 변동</td>
</tr>
<tr>
<td>일라이 릴리 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)</td>
<td>-4.35%</td>
<td>-7.35%</td>
<td>-5.09%</td>
</tr>
<tr>
<td>애브비 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</td>
<td>-3.14%</td>
<td>-2.92%</td>
<td>3.99%</td>
</tr>
<tr>
<td>브리스톨 마이어스 스퀴브 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</td>
<td>-6.10%</td>
<td>-11.15%</td>
<td>2.73%</td>
</tr>
<tr>
<td>리제네론 파마슈티컬스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)</td>
<td>-5.26%</td>
<td>-23.60%</td>
<td>-40.63%</td>
</tr>
<tr>
<td>화이자 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</td>
<td>-3.87%</td>
<td>-18.87%</td>
<td>-18.03%</td>
</tr>
<tr>
<td>길리어드 사이언스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)</td>
<td>-3.66%</td>
<td>10.36%</td>
<td>47.71%</td>
</tr>
<tr>
<td>머크 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</td>
<td>-5.32%</td>
<td>-21.80%</td>
<td>-38.53%</td>
</tr>
<tr>
<td>암젠 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)</td>
<td>-3.33%</td>
<td>8.54%</td>
<td>4.23%</td>
</tr>
<tr>
<td>존슨앤드본슨 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</td>
<td>-1.51%</td>
<td>3.24%</td>
<td>-0.07%</td>
</tr>
</tbody>
</table>
</figure>
왜 중요한가: 90일간의 상호 관세 유예에도 불구하고 10%의 글로벌 기본 관세와 125%의 중국 관세, 그리고 철강 및 알루미늄, 자동차, 자동차 부품에 대한 25%의 부문별 관세는 그대로 유지된다. 여기에 더해 트럼프 대통령은 곧 제약사에 대한 관세를 발표할 수 있음을 시사했다.
영향을 받을 수 있는 제약 산업 관련 상장지수펀드는 다음과 같다.
<figure class="wp-block-table is-style-stripes">
<table style="overflow:auto; height: 90px; display: block;">
<tbody>
<tr>
<td>제약 ETF</td>
<td>2025년 변동</td>
<td>지난 1년 변동</td>
</tr>
<tr>
<td>VanEck Pharmaceutical ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPH#NASDAQ">PPH</a>)</td>
<td>-7.02%</td>
<td>-7.51%</td>
</tr>
<tr>
<td>iShares US Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)</td>
<td>-7.04%</td>
<td>-6.08%</td>
</tr>
<tr>
<td>Invesco Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJP#NYSE">PJP</a>)</td>
<td>-10.13%</td>
<td>-4.37%</td>
</tr>
<tr>
<td>SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>)</td>
<td>-14.05%</td>
<td>-11.45%</td>
</tr>
<tr>
<td>KraneShares MSCI All China Health Care Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KURE#NYSE">KURE</a>)</td>
<td>2.88%</td>
<td>0.35%</td>
</tr>
<tr>
<td>First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXH#NASDAQ">FTXH</a>)</td>
<td>-11.54%</td>
<td>-10.18%</td>
</tr>
<tr>
<td>Direxion Daily Pharmaceutical &amp; Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PILL#NYSE">PILL</a>)</td>
<td>-41.35%</td>
<td>-43.86%</td>
</tr>
</tbody>
</table>
</figure>
가격 움직임: 목요일 하락 후 수요일 반등에 이어 나스닥 100 지수는 전고점인 22,222.61포인트보다 17.46% 하락했다. S&amp;P 500 지수는 전고점인 6,147.43포인트 대비 14.31% 하락했고, 다우존스 지수는 52주 최고치인 45,073.63포인트 대비 12.16% 하락했다.
각각 S&amp;P 500 지수와 나스닥 100 지수를 추종하는 SPDR S&amp;P 500 ETF 신탁(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)과 인베스코 QQQ 신탁 ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)는 목요일에 하락 마감했다. SPY는 524.58달러로 4.38% 하락했고, QQQ는 446.18달러로 4.25% 하락했다.
사진 제공: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Direxion Daily Pharmaceutical & Medical Bull 3X Shares

뉴스

에 대한 최신 뉴스 Direxion Daily Pharmaceutical & Medical Bull 3X Shares (ARCA:PILL)

월요일, 5월 19, 2025

금요일, 4월 11, 2025

뉴스

파트너 / 기고자

벤징가 글로벌